← All trials
NCT07307794
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- Dec 29, 2025
- Last posted
- Dec 29, 2025
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- ClinSearch, LLCCollaborator
- CRM Biometrics GmbHCollaborator
- HWI pharma services GmbHCollaborator
- SocraMetrics GmbHCollaborator
- SocraTec R&D GmbHCollaborator
- Teikoku Seiyaku Co., Ltd.Official
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.